Table 3.

Prognostic value of DUSP5 expression for the biochemical recurrence-free survival in univariate and multivariate analysis by Cox Regression

	Univaviable analysis		Multivaviable analysis
	HR (95% CI)	P	HR (95% CI)	P
Preoperative PSA	1.23 (0.52-2.93)	0.642	0.81 (0.33-1.98)	0.644
Clinical tumor stage	1.1 (0.578-2.018)	0.81	0.78 (0.4-1.51)	0.46
Pathological tumor stage	5.81 (2.95-11.42)	< 0.001	3.37 (1.61-7.03)	0.001
Gleason score	7.67 (4.38-13.42)	< 0.001	5.72 (3.19-10.27)	< 0.001
DUSP5	0.42 (0.22-0.82)	0.011	0.41 (0.2-0.82)	0.012

HR, Hazard ratio; CI, confidence interval; Preoperative PSA (ng/ml), between ≤ 4 and > 4; Clinical tumor stage, between < T2A and ≥ T2A; Pathological tumor stage, between T2A-T2C and T3A-T4; Gleason score, among Gleason score ≤ 6, 7 and ≥ 8; DUSP5, continuous DUSP5 expression levels.